REG - Novacyt S.A. - Full year trading update

Novacyt SAAnnouncement

21/01/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260121:nRSU6401Pa&default-theme=true

RNS Number : 6401P  Novacyt S.A.  21 January 2026

 

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

 

Full year trading update

 

Paris, France and Manchester, UK - 21 January 2026 - Novacyt (EURONEXT
GROWTH: ALNOV; AIM: NCYT), the international molecular diagnostics company
with a broad portfolio of integrated technologies and services, announces an
unaudited full year trading update for the year ended 31 December 2025 ("FY
2025"), a period where revenues met market expectations, the Group maintained
sequential half-year revenue growth and the cash position remained strong.

 

Financial highlights (unaudited)

·    Group statutory revenue for FY 2025 is expected to be c. £20.0m (FY
2024: £19.6m), in line with market expectations of £19.8m

·    Underlying Group revenue grew by c.4% (5% on a constant currency
basis), excluding the impact of the Taiwan service laboratory divestment

·    Clinical segment delivered sales of £13.8m, (FY 2024: £13.5m),
representing growth of 3%, driven by the acquisition of a new strategic
customer in the APAC region

-      Within this segment NIPT technologies was up over 10% year-on-year

·    Instrumentation segment delivered more than 25% growth in sales to
£2.5m, (FY 2024: £2.0m) predominantly driven by the LightBench® Discover
instrument

·    RUO segment declined year-on-year by c. 10% to £3.7m (FY 2024:
£4.2m), as a result of reduced sales of the Primerdesign catalogue of
products

·    APAC region delivered the highest year-on-year growth of c. 10%
achieving sales of £5.5m, driven by the continued strong demand for the
Company's Reproductive Health range of products, followed by the Americas
region delivering growth of c. 8%

·    Group maintained sequential half-year growth over three consecutive
periods, with revenue rising from £9.6m in H2 2024 to £10.2m in H2 2025

·    EBITDA losses will at least meet, or show an improvement to, market
expectations, as a result of careful cost management

·    Cash position at 31 December 2025 was £19.2m (30 June 2025:
£23.8m), and the Group remains debt free

 

The Board understands that market expectations for the year ended 31 December
2025 to be revenue of £19.8m, an adjusted EBITDA loss of £8.5m and a closing
cash balance of £18.8m.

 

Commercial progress

The Instrumentation segment delivered more than 25% revenue growth in the
period, predominately driven by the launch of the LightBench® Discover
instrument, a high-precision 3-in-1 instrument for genomic research labs
conducting long-read sequencing. Since its launch in July 2025, the Company
has successfully placed 10 instruments, with multiple collaborations secured
and demonstrations to customers delivered. The Group confirms a healthy
pipeline of opportunities for 2026 and beyond, as customers proactively reach
out to learn more about this technology.

 

Despite the decline in sales within the Company's RUO segment, the Group
successfully launched Primerdesign exsig® Mag RapidBead Pro Extraction Kit in
November 2025. The cost-efficient, end-to-end solution, delivers superior
performance for the Group's partners, setting a new standard for DNA/RNA
purification. Combining the proven reliability of the exsig® Mag kit and the
speed of a next-generation rapid extraction workflow, the kit helps
researchers accelerate molecular discovery and pathogen testing from sample to
results.

 

Finally, Beta testing is underway with international key opinion leaders in
the field of precision medicine for Yourgene's Insight DPYD assay, the
enhanced DPYD test which helps identify cancer patients at risk of suffering a
severe and potentially life-threatening reaction to common chemotherapy. This
Beta testing has commenced in good time, ahead of the product launch expected
in H1 2026.

 

Final results

The Group expects to report its full year results for the year ended 31
December 2025 during April 2026.

 

Commenting on the trading update Lyn Rees, CEO of Novacyt, said: "With the
period of restructuring and integration completed, and the successful derisked
and stabilised business formed, we committed as a Board to deliver top line
growth. We're therefore pleased to have delivered year on year revenue growth
in line with market expectations. It's also pleasing to report two consecutive
periods of half-year growth underpinned by an upward trajectory of revenue
growth. These results prove the strong foundation we have created as a Group,
and we look forward to driving innovation further as we continue to execute
and deliver on our plans."

 

This announcement contains inside information for the purposes of Article 7 of
Regulation (EU) 596/2014.

 

 

 

Contacts

 

 Novacyt SA                                                              https://novacyt.com/investors (https://novacyt.com/investors/)
 Lyn Rees, Chief Executive Officer                                        Via Walbrook PR
 Steve Gibson, Chief Financial Officer

 SP Angel Corporate Finance LLP (Nominated Adviser and Broker)                                             +44 (0)20 3470 0470
 Matthew Johnson / Charlie Bouverat (Corporate Finance)

 Vadim Alexandre / Rob Rees (Corporate Broking)

 Singer Capital Markets (Joint Broker)                                                                     +44 (0) 20 7496 3000
 Phil Davies / James Fischer / Samed Ethemi

 Allegra Finance (French Listing Sponsor)       +33 (1) 42 22 10 10

                                             r.durgetto@allegrafinance.com (mailto:r.durgetto@allegrafinance.com) /
 Rémi Durgetto / Yannick Petit                 y.petit@allegrafinance.com

 Walbrook PR (Financial PR & IR)                                         +44 (0)20 7933 8780 or novacyt@walbrookpr.com

 Paul McManus / Lianne Applegarth                                        +44 (0)7980 541 893 / +44 (0)7584 391 303

 Alice Woodings                                                           +44 (0)7407 804 654

 

 

About Novacyt Group (www.novacyt.com (http://www.novacyt.com) )

Novacyt is an international molecular diagnostics company providing a broad
portfolio of integrated technologies and services, primarily focused on the
delivery of genomic medicine. The Company develops, manufactures, and
commercialises a range of molecular assays and instrumentation to deliver
workflows and services that enable seamless end-to-end solutions from sample
to result across multiple sectors including human health, animal health and
environmental.

 

The Company is divided into three business segments:

 

 Clinical             Broad portfolio of human clinical in vitro diagnostic products, workflows and
                      services focused on three therapeutic areas:

                      ·    Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy
                      tests

                      ·    Precision Medicine: DPYD genotyping assay

                      ·    Infectious Diseases: Winterplex, multiplex winter respiratory PCR
                      panel

 Instrumentation      Portfolio of next generation size selection DNA sample preparation platforms
                      and rapid PCR machines, including:

                      ·    Ranger® Technology: automated DNA sample preparation and target
                      enrichment technology

                      ·    genesig q16 and q32 real-time quantitative PCR (qPCR) instruments

 Research Use Only    Range of services for the life sciences industry:

                      ·    Design, manufacture, and supply of high-performance qPCR assays and
                      workflows for use in human health, agriculture, veterinary and environmental,
                      to support global health organisations and the research industry

                      ·    Pharmaceutical research services: whole genome sequencing (WGS) /
                      whole exome sequencing (WES)

 

Novacyt is headquartered in Le Vésinet in France with offices in the UK (in
Manchester), Singapore, the US and Canada and has a commercial presence in
over 65 countries. The Company is listed on the London Stock Exchange's AIM
market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

 

For more information, please refer to the website: www.novacyt.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTBSGDBRXDDGLG



            Copyright 2019 Regulatory News Service, all rights reserved